Legal & General Group’s MiNK Therapeutics INKT Stock Holding History

Legal & General Group’s Portfolio INKT Stock Details INKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1	Closed	-$16	–	3417
2023 Q2	$16	Buy	+1	New	+$20	﹤0.01%	3405

Other funds holding INKT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Legal & General Group's INKT Position: Q3 2023 in Review

Legal & General Group sold out of MiNK Therapeutics (INKT) in Q3 2023, closing a stake of 1 share — an estimated $16 sold.

Legal & General Group first reported a position in INKT in Q2 2023 and held it in 1 quarter. The position peaked at $16 in Q2 2023. 34 funds tracked by Wall St. Rank hold INKT as of Q3 2023.

Legal & General Group reported no remaining MiNK Therapeutics position as of Q3 2023 after selling out during the quarter.
Legal & General Group sold 1 MiNK Therapeutics share in Q3 2023, an estimated $16.
Legal & General Group first reported a position in MiNK Therapeutics in Q2 2023 and held it in 1 quarter.
Legal & General Group's MiNK Therapeutics position peaked at $16 in Q2 2023.
34 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q3 2023.

Based on Legal & General Group's 13F filing for Q3 2023, filed 14 Nov 2023.